ijms-logo

Journal Browser

Journal Browser

B Cell Lymphoma: From Pathogenesis to Treatment

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 1842

Special Issue Editor


E-Mail Website
Guest Editor
Instituto Nacional de Cancerología, Mexico City, Mexico
Interests: lymphoma; non-Hodgkin lymphoma; B cell lymphoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lymphomas comprise a heterogeneous group of hematological malignancies classified according to their clinical, anatomopathological, and molecular features. Diffuse large B cell lymphoma (DLBCL) is the most common B cell malignancy worldwide. The incidence of DLBCL increases from 45 cases to 112 per 100,000 people in patients aged 60–64 years and 80–84 years, respectively.

In recent years, numerous genomic sequencing studies have primarily targeted recurrent mutations in individual genes, elucidating underlying oncogenic mechanisms, and recently molecular classifications have deepened our understanding of DLBCL and begun to offer a pathway to improve cure rates by clustering high-risk populations. Therefore, a deeper and detailed analysis using genomic, transcriptome, and epigenetic data has been performed by different groups, refining the classification of DLBCL into clusters with an impact on clinical outcomes. For more than two decades, the combination of rituximab, an anti-CD-20 antibody, and chemotherapy has been the standard of care of such a kind of malignancy, and new options have failed to improve the outcome.

We aim for this Special Issue to cover in-depth reviews and research regarding the role of epigenetic regulation, genes implicated in cell cycle control, proliferation, and apoptosis; the most important biological processes participating in pathogenesis may have an impact on the treatment and outcome of such patients.

Dr. Myrna Gloria Candelaria
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-Hodgkin lymphoma pathogenesis
  • B cell lymphoma regulation
  • epigenetics and B cell lymphoma
  • bispecific antibodies in lymphoma
  • epigenetics in B cell lymphoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2378 KiB  
Article
Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients
by Myrna Candelaria, Dennis Cerrato-Izaguirre, Olga Gutierrez, Jose Diaz-Chavez, Alejandro Aviles, Alfonso Dueñas-Gonzalez and Luis Malpica
Int. J. Mol. Sci. 2024, 25(17), 9328; https://doi.org/10.3390/ijms25179328 - 28 Aug 2024
Viewed by 1289
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell malignancy worldwide. Molecular classifications have tried to improve cure rates. We prospectively examined and correlated the mutational landscape with the clinical features and outcomes of 185 Mexican patients (median age 59.3 years, 50% [...] Read more.
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell malignancy worldwide. Molecular classifications have tried to improve cure rates. We prospectively examined and correlated the mutational landscape with the clinical features and outcomes of 185 Mexican patients (median age 59.3 years, 50% women) with newly diagnosed DLBCL. A customized panel of 79 genes was designed, based on previous international series. Most patients had ECOG performance status (PS) < 2 (69.2%), advanced-stage disease (72.4%), germinal-center phenotype (68.1%), and double-hit lymphomas (14.1%). One hundred and ten (59.5%) patients had at least one gene with driver mutations. The most common mutated genes were as follows: TP53, EZH2, CREBBP, NOTCH1, and KMT2D. The median follow-up was 42 months, and the 5-year relapse-free survival (RFS) and overall survival (OS) rates were 70% and 72%, respectively. In the multivariate analysis, both age > 50 years and ECOG PS > 2 were significantly associated with a worse OS. Our investigation did not reveal any discernible correlation between the presence of a specific mutation and survival. In conclusion, using a customized panel, we characterized the mutational landscape of a large cohort of Mexican DLBCL patients. These results need to be confirmed in further studies. Full article
(This article belongs to the Special Issue B Cell Lymphoma: From Pathogenesis to Treatment)
Show Figures

Figure 1

Back to TopTop